Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 17;7(1):8649.
doi: 10.1038/s41598-017-08851-9.

Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma

Dongjun Jeong  1 , Seona Ban  2 , Seunghyun Oh  2 , Su Jin Lee  3 , Seong Yong Park  4 , Young Wha Koh  5
Affiliations

Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma

Dongjun Jeong et al. Sci Rep. .

Abstract

We examined the prognostic significance of Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3 (EDIL3) expression and its correlations with mesenchymal phenotype and microvessel density in non-small cell lung carcinoma (NSCLC). A total of 268 NSCLC specimens were evaluated retrospectively by immunohistochemical staining for EDIL3, EMT markers (e-cadherin, β-catenin, and vimentin), and CD31 to measure microvessel density. EDIL3, e-cadherin, β-catenin, and vimentin were expressed in 16%, 22.8%, 3.7%, and 10.1% of the specimens, respectively. The mRNA level of EDIL3 in tumor was correlated with the level of EDIL3 protein expression using immunohistochemistry. In lung adenocarcinoma patients, EDIL3 expression was significantly correlated with low e-cadherin expression, high vimentin expression, and increased microvessel density (P < 0.001, P = 0.001, and P = 0.023, respectively). In lung squamous cell carcinoma patients, EDIL3 expression was significantly correlated with low e-cadherin expression and high vimentin expression (P = 0.021 and P = 0.002, respectively). In lung adenocarcinoma patients, EDIL3 was an independent prognostic factor for overall survival in a multivariate analysis (hazard ratio: 2.552, P = 0.004). EDIL3 is significantly correlated with mesenchymal phenotype, angiogenesis, and tumor progression in lung adenocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
EDIL3, e-cadherin, vimentin, and CD31 expression in lung adenocarcinoma and tumor-free control lung samples. (A) Positive EDIL3 expression on tumor cells(x400). (B) Negative EDIL3 expression on tumor cells(x400). (C) Faint positive EDIL3 expression on macrophages (arrow) and lymphocyte (arrowhead) and negative expression of pneumocyte and endothelial cells of control sample (x400). (D) Positive e-cadherin expression on tumor cells(x400). (E) Negative e-cadherin expression on tumor cells(x400). (F) Positive e-cadherin expression on pneumocyte of control sample(x400). (G) Positive vimentin expression on tumor cells(x400). (H) Negative vimentin expression on tumor cells(x400). (I) Positive vimentin expression on capillary and macrophage of control sample (x400). (J) High microvessel density with CD31 expression on tumor. (x200). (K) Low microvessel density with CD31 expression on tumor(x200). (L) Positive CD31 expression on capillary of control sample (x200).
Figure 2
Figure 2
Correlation between EDIL3 protein expression and EDIL3 mRNA expression. The mRNA level in tumors positive for EDIL3 immunohistochemistry was higher than that in tumor-free control lung samples and tumors without EDIL3 immunohistochemical positivity.
Figure 3
Figure 3
Correlation between EDIL3 and microvessel density. (A) All NSCLC patients. (B) adenocarcinoma patients. (C) squamous cell carcinoma patients.
Figure 4
Figure 4
Comparison of survival rates according to EDIL3 expression in tumor cells. (A) All NSCLC patients. (B) adenocarcinoma patients. (C) squamous cell carcinoma patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65:5–29. - PubMed
    1. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine. 2002;346:92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Wijesinghe P, Bollig-Fischer A. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in experimental medicine and biology. 2016;890:1–23. doi: 10.1007/978-3-319-24932-2_1. - DOI - PubMed
    1. Nascimento AV, Bousbaa H, Ferreira D, Sarmento B. Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy. Current drug targets. 2015;16:1448–1463. doi: 10.2174/1389450115666140528151649. - DOI - PubMed
    1. Hidai C, Kawana M, Kitano H, Kokubun S. Discoidin domain of Del1 protein contributes to its deposition in the extracellular matrix. Cell and tissue research. 2007;330:83–95. doi: 10.1007/s00441-007-0456-9. - DOI - PubMed

MeSH terms

LinkOut - more resources